Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 572.90 INR
Change Today +8.55 / 1.52%
Volume 31.0K
ARTD On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

aarti drugs ltd (ARTD) Snapshot

Open
574.00
Previous Close
564.35
Day High
585.65
Day Low
570.05
52 Week High
04/8/15 - 874.90
52 Week Low
10/21/14 - 333.30
Market Cap
13.9B
Average Volume 10 Days
58.6K
EPS TTM
31.90
Shares Outstanding
24.2M
EX-Date
08/5/15
P/E TM
18.0x
Dividend
8.00
Dividend Yield
1.40%
Current Stock Chart for AARTI DRUGS LTD (ARTD)

Related News

No related news articles were found.

aarti drugs ltd (ARTD) Related Businessweek News

No Related Businessweek News Found

aarti drugs ltd (ARTD) Details

Aarti Drugs Limited engages in pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals/antiprotozoles, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, alzheimer’s treatment, antiBPH, sedatives, and vitamins. The company also provides pharmaceutical intermediate products; steroids comprising hydrocortisone sodium succinate sterile, acetate, and hemisuccinate; and specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, methyl nicotinate, N-methyl methane sulphonamide, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, and para toluene sulphonyl chloride. In addition, its products under development comprises Acamprosate for the treatment of alcoholism; Dabigatran for use as an anticoagulants; Sevelamer for the treatment of antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as antidiabetic. The company also exports its products, as well as offers contract manufacturing services. Aarti Drugs Limited was founded in 1984 and is based in Mumbai, India.

Founded in 1984

aarti drugs ltd (ARTD) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: 6.6M
Managing Director, Whole-Time Director, Membe...
Total Annual Compensation: 6.1M
Joint Managing Director, Executive Director, ...
Total Annual Compensation: 6.0M
Chief Financial Officer
Total Annual Compensation: 3.1M
Whole-Time Director, Member of Share Transfer...
Total Annual Compensation: 6.0M
Compensation as of Fiscal Year 2015.

aarti drugs ltd (ARTD) Key Developments

Aarti Drugs Limited Announces Audited Earnings Results for the First Quarter Ended June 30, 2015

Aarti Drugs Limited announced audited earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of INR 2,632.9 million against INR 2,596.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 348.4 million against INR 324.5 million a year ago. Profit from ordinary activities before tax was INR 245.5 million against INR 226.2 million a year ago. Net profit was INR 170.5 million against INR 172.4 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 7.04 against INR 7.12 a year ago.

Aarti Drugs Limited, Annual General Meeting, Aug 14, 2015

Aarti Drugs Limited, Annual General Meeting, Aug 14, 2015.

Aarti Drugs Limited to Report Q1, 2016 Results on Jul 31, 2015

Aarti Drugs Limited announced that they will report Q1, 2016 results on Jul 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARTD:IN 572.90 INR +8.55

ARTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARTD.
View Industry Companies
 

Industry Analysis

ARTD

Industry Average

Valuation ARTD Industry Range
Price/Earnings 17.3x
Price/Sales 1.2x
Price/Book -- Not Meaningful
Price/Cash Flow 12.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AARTI DRUGS LTD, please visit www.aartidrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.